Clinical Trials Logo

Clinical Trial Summary

Liver transplantation is currently an effective treatment for end-stage liver disease. The high incidence of thrombotic related complications in the early postoperative period after orthotopic liver transplantation(OLT) has been attributed to many factors, such as the long operation time, the high trauma, the need for prolonged bed rest after operation, and the instability of coagulation status in the early postoperative period. Among them, venous thromboembolism (VTE) is one of the most common complications after liver transplantation, including deep vein thrombosis (DVT) and pulmonary embolism (PE), which seriously affect the survival of patients after transplantation. Although the Caprini score is currently recognized as a more mature thrombotic risk assessment tool in patients undergoing abdominal surgery. However, because of the long operation time of liver transplantation and central venous catheterization and other factors, the majority of surgical patients score ≥ 5 points, which are all very high-risk grades. It loses the power of this model for risk stratification and targeted prevention. How to correctly identify people at high risk of VTE after OLT, early diagnosis of VTE and aggressive implementation of correct preventive measures appear essential. Therefore, this study was designed as a single center case-control study to review and analyze the incidence, clinical characteristics, and associated risk factors of VTE after OLT, and to establish a nomogram risk assessment model and validate its predictive efficacy.


Clinical Trial Description

In this study, the investigators recruited adult inpatients who underwent orthotopic liver transplantation at Tsinghua Chang Gung Memorial Hospital, Beijing, from August 2018 to December 2021. The hospitalized patients who developed VTE within 30 days after liver transplantation were screened according to the inclusion and exclusion criteria, and similarly, the negative patients were those who did not develop VTE perioperatively or who developed VTE greater than 30 days postoperatively. The diagnosis of VTE was confirmed as the occurrence of a critical value alert during hospitalization, which was predefined as ultrasound/radiology report of DVT or/and PE. Data were obtained from the medical record bank of Tsinghua Chang Gung Memorial Hospital, affiliated to Tsinghua University, Beijing, China. Patient general data, laboratory test data, surgical information, etc. were extracted from the database. To analyze the incidence, clinical characteristics, and risk factors of VTE in patients after liver transplantation. Based on risk factors, a risk assessment model was built with liver transplant inpatient data from August 2018 to December 2020, and the model was validated with liver transplant inpatient data from January 2021 to December 2021. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05209048
Study type Observational
Source Beijing Tsinghua Chang Gung Hospital
Contact
Status Completed
Phase
Start date August 1, 2018
Completion date December 31, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT03691753 - Safety and Efficacy Study of Fitaya Vena Cava Filter N/A
Completed NCT02197416 - Safety of Dabigatran Etexilate in Blood Clot Prevention in Children Phase 3
Completed NCT01895777 - Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE) Phase 3
Active, not recruiting NCT04736719 - Replication of the AMPLIFY Anticoagulant Trial in Healthcare Claims Data
Active, not recruiting NCT04735523 - Replication of the RECOVER-II Anticoagulant Trial in Healthcare Claims Data
Completed NCT04736420 - Replication of the EINSTEIN-DVT Anticoagulant Trial in Healthcare Claims Data
Not yet recruiting NCT04766216 - Warfarin Patient Self-management Implementation in the US Healthcare System N/A
Not yet recruiting NCT05029063 - Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters Phase 3
Recruiting NCT02829957 - RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding Phase 2/Phase 3
Completed NCT02912234 - Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants Phase 1
Completed NCT02746185 - Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban Phase 3
Recruiting NCT02379806 - The SYMPTOMS - SYstematic Elderly Medical Patients Thromboprophylaxis: Efficacy on Symptomatic OutcoMeS - Study Phase 3
Completed NCT02334007 - Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery Phase 1/Phase 2
Completed NCT02223260 - Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of Age Phase 2
Completed NCT02661568 - Description of Patients With Acute Venous Thromboembolism in the UK's Clinical Practice Research Datalink Linked With Hospital Episode Statistics Dataset (CPRD-HES) N/A
Recruiting NCT01972243 - Risk of Recurrent Venous Thrombosis: A Validation Study of the Vienna Prediction Model N/A
Completed NCT01976988 - Prospective Study on Preoperative Versus Postoperative Venous Thromboprophylaxis in Patients Undergoing Major Colorectal Surgery Phase 3
Completed NCT01431456 - Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery Phase 3
Not yet recruiting NCT01357941 - Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE) N/A
Withdrawn NCT01446510 - Systematic Review and Meta-Analysis of Venous Thromboembolism (VTE) Risk Assessment in Hospitalized Medical Patients N/A